Efficacy of dalbavancin in osteoarticular infections associated with hip, knee and shoulder prostheses PRO-DALBA

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518183-12-00

Acronym

20-AOI-03

Enrollment

Registered

2024-10-14

Start date

2022-03-07

Completion date

Unknown

Last updated

2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prosthetic joint infections

Brief summary

Success is defined as the absence of failure within 12 months of surgical management.

Detailed description

Success is defined as the absence of failure within 24 months of surgical management., Tolerability will be assessed by collecting adverse events during treatment with dalbavancin and rifampicin classified according to CTCAE (version 5.0) within 6 months of first administration., Residual dose of dalbavancin at D61

Interventions

DRUGRIFAMPICIN

DRUGXydalba 500 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Success is defined as the absence of failure within 12 months of surgical management.	—

Secondary

Measure	Time frame
Success is defined as the absence of failure within 24 months of surgical management., Tolerability will be assessed by collecting adverse events during treatment with dalbavancin and rifampicin classified according to CTCAE (version 5.0) within 6 months of first administration., Residual dose of dalbavancin at D61	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026